A definitive cure for at least five major cancers is approved within 10 years.

Question

Six frontier AI models put this at 7% by 1 Oct 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

7% — the median of 6 frontier models, resolving by 2036-10-01.

Answer

Gemini (Google): 4% — Oncologic heterogeneity makes broad definitive cures exceedingly rare across multiple distinct major malignancies in one decade. Clinical trials must demonstrate durable, near-total remission over 5-year follow-ups, leaving insufficient time by 2036. Regulators like the FDA define efficacy via progression-free survival rather than definitive eradication for solid tumors. Major cancers (lung, breast, colorectal, prostate, pancreas) possess divergent genomic drivers that resist universal therapies.

Answer

Claude (Anthropic): 3% — Oncology relies on remission/survival endpoints, not 'cure' labels, so regulatory approval of 'cures' for five cancers is almost unprecedented. FDA/EMA approvals use endpoints like overall survival or progression-free survival, never a formal 'cure' designation, making literal resolution nearly impossible. Even major breakthroughs like CAR-T or checkpoint inhibitors took decades and only achieved durable remission in subsets of patients, not universal cures. A paradigm shift in regulatory language or an extraordinary efficacy breakthrough across five distinct cancer types within 10 years would be needed to change this.

Answer

GPT (OpenAI): 9% — This hinges on regulators accepting durable, broadly curative outcomes—not incremental survival gains—in five distinct common cancers. FDA/EMA would need approvals by 1 October 2036, after randomized trials show near-elimination of recurrence across major tumor types. No systemic therapy has yet delivered a regulator-labeled definitive cure for a common advanced solid cancer; ten years is short for Phase III follow-up. Odds rise sharply if several personalized neoantigen or cell therapies show 10-year disease-free survival in pancreatic, lung, colorectal, breast, or prostate cancer.

Answer

Grok (xAI): 12% — Five major-cancer ‘cures’ need Phase-3 proof of near-100% durable CR plus FDA/EMA nods by 2036. FDA/EMA must see multi-year, high-CR data in five high-incidence tumors (lung, breast, CRC, prostate, pancreas); typical oncology Phase 3 + review still takes 6–8 years. Base rate: zero such approvals for common solid tumors in the last 20 years despite checkpoint inhibitors and CAR-T; mRNA/TIL programs remain early and tumor-specific. A single pan-cancer platform showing 80%+ 5-year DFS in two large Phase 3s by 2030 would raise odds sharply; anything less keeps the bar unmet.

Answer

DeepSeek (DeepSeek): 12% — Ten years is roughly one drug-development cycle; five distinct cancer cures clearing FDA by 2036 needs a pace oncology has never shown. FDA approves roughly 15-20 novel oncology drugs a year, but almost none are 'cures' — most add months of progression-free survival, not durable remission. The closest precedents are CAR-T in blood cancers (Kymriah 2017) and checkpoint inhibitors in melanoma; after 15 years these still cover a handful of histologies, not… Five major cancers means breast, lung, colorectal, prostate, pancreas or similar — solid tumors with heterogeneous antigens, where mRNA and cell therapies have…

Answer

Qwen (Alibaba): 4% — A 'definitive cure' for five major cancers is an extraordinarily high bar that no current pipeline realistically clears in a decade. FDA approval of a cancer 'cure' (not just treatment) has never happened for any solid tumor; the bar requires near-complete eradication, not improved survival. Even the most promising CAR-T and mRNA candidates (e.g., Moderna/Merck mRNA-4157 for melanoma) are in Phase II/III and show improved outcomes, not cures. Five separate approvals would require five independent pipelines to each leap from promising to curative—a compound improbability with no historical precedent.

A definitive cure for at least five major cancers is approved within 10 years.

A clinically proven cure for dementia is approved before 2032.

A disease-reversing cure for Alzheimer's disease receives FDA approval before 2035.

A definitive cure for cancer is developed and approved within 20 years.

An FDA-approved universal cure for all major forms of cancer is available before 2035.